{"name":"EyeD Pharma","slug":"eyed-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNclNxVmpuOXVieWUyR0JMc2V1SnJNVjVyMC1GazVVOXhXVi1TQzNRczRmOU90OThNYmhaM0NJeHRvcGxVbkp0Mk80OTNFYjVTbzdQMHVBUjdIT3UzNmlLQzRZODcxMEY2dk5VN2pOTzZnQ1Q3ejlUYU1zZEhPLTFaeWRBYjZPQUtDVVRzSU9rb3hneFotUS1WLXI4cTR6LTBGRlQ0SWlVVFJaWEFuTlFaYjBR?oc=5","date":"2026-04-07","type":"pipeline","source":"MSN","summary":"Trump announces 100% tariff on pharma imports; India impact eyed - MSN","headline":"Trump announces 100% tariff on pharma imports; India impact eyed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPRUZRWndUT2VUN0hJdlEwTjd6d29pWTNqcWhuUUxFQm1vM3hMMXl4ZnNzWDdIeGdhb2MxZTNhVmhBNTZaNmdWMGFUYXVJVUlWYkZqSE1COXpwclhNX1gxQVVUWTdZZnozalpDRkxQcXNzalJ0clRtVzliVTdsY3lnenRIbHpXNXlLUkFkZEhfWnBRRkRWeUFFUjVDZjNadw?oc=5","date":"2026-04-03","type":"pipeline","source":"Yicai Global","summary":"Bayer Deepens China Innovation Bet as Pharma Unit Eyes 30% Margin - Yicai Global","headline":"Bayer Deepens China Innovation Bet as Pharma Unit Eyes 30% Margin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNZXNPLWFPbnBVUXJoaGVtLV9xRmRsYm15cjUydnA5WmgzMURZQTRmVVFMYzJYWVVfdnplMTRCWFhxaXZ5NTJRUFVJbUNRaEplTmxfSXhwTEVGNkxzbTUzWi1ITTBrLVE2Yy05akM4a2R3SUlEYWtJaG9naDdwc1lXNlBfSmlmOWFzbWxnaXIzbWpRb1JLOVJSVnNJMDhDX3ZKRnFTbnZqVGl1RnNGSVp5c0hTanV6MGRBNkpTX095YTdPTWh4Ykg5My1WUGtNaW90OTBfSXFQVVB5QQ?oc=5","date":"2026-03-06","type":"earnings","source":"Investor's Business Daily","summary":"This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% - Investor's Business Daily","headline":"This Pharma Stock Shows Strength, Eyes Entry As Earnings Surge 59% - Investor's Business Daily","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPbGxfc0NtWVRodFNJbDZrS2RKaFZhNnY1bzVVUnhIYmRsMTFCc2RDQXB6ZVNZV0ZKa0ZPLTdOd2FObzliS0ptRjhGVWIyd0FYVU00cmlqSjg5N3JoSlljU2dtQmYyQnhrLVlzUjdJbWJhbm15cHBzZjQ0NjltOHNLZjN0TQ?oc=5","date":"2026-02-13","type":"trial","source":"Yahoo Finance","summary":"OKYO Pharma prices $20M offering to fund late-stage eye drug trial - Yahoo Finance","headline":"OKYO Pharma prices $20M offering to fund late-stage eye drug trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQV2dNLW5VakhHdnJBbElyNkpGQmRNcW10UHd4RzQ0c0lDRmdmS3ZyOEp2MUdYTDJIOG51bjRaaTZXN3pYWW42c0VJcTNPLXFucmVZVTg2Z1hIUTY1aUd3WWdUZXJJWnQ3bS16ZktRdlBlSkw0MGoxVmNIVVl3RER1TXV6RDdoUF9EZlZZeFVwZ2VHZlY5a1NGbXBvc3BzZi1xM2ZVQnBzbG94NkNLNjhFdlE3ZVp4RTllQmc?oc=5","date":"2026-02-09","type":"earnings","source":"Pharmaceutical Technology","summary":"Pharma eyes AI deals to stem lost revenues from patent expirations - Pharmaceutical Technology","headline":"Pharma eyes AI deals to stem lost revenues from patent expirations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNQ1Fjb3lHY1M4VWtRLTA2RWcwdW1Ndy1WUjd0cDFyOXY5QTliVFh0MjR0WHl3TVlHNnIxV3V2ZWJNdzctTUxzZ0J5ZGJKeWw2OV9rWk5WN1h1a05NRXpYeU9tcW4wYU41ZzdHQjF2RXpNeEh4azQzQzdBV25BY0c5ZFRON1BWbmNfcVhSa3ZKWG9mbGd0aDQtOE5KWlBXNnhXT1g1TFNrQ2dvNkdwYVdlUWZ5Z044VlJETTZaVmVkTVVrcHE4cnRwbFp2QmhKQQ?oc=5","date":"2026-01-29","type":"pipeline","source":"renaissancecapital.com","summary":"SGP IPO News - Chronic eye condition biotech SpyGlass Pharma sets terms for $150 million IPO - renaissancecapital.com","headline":"SGP IPO News - Chronic eye condition biotech SpyGlass Pharma sets terms for $150 million IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPYUVrREZOVmx4Q3NJdkRCajh6dWFuajI5dk5pRFNJcVRqYmJlQm9tVjJiTmpNWVBEcXdNRUVrMElZWnRDT3FTZzhNdjgwN1N0anYtbnlSV1A4QnF6T1FrZEFNTkRyZGl0ZmlTeVp0LVM2QWNvekt6eUVVT2ZfU0QxOTlISDVfdnlUTkM1YzFBaEVSM29wSDNJdkNn?oc=5","date":"2026-01-29","type":"regulatory","source":"fiercepharma.com","summary":"Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow - fiercepharma.com","headline":"Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-23","type":"pipeline","source":"South China Morning Post","summary":"China’s Fosun Pharma eyes spin-off Hong Kong IPO of vaccine unit - South China Morning Post","headline":"China’s Fosun Pharma eyes spin-off Hong Kong IPO of vaccine unit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQQlhPdnNKc05FOS1BdHZNeEE3UzFRZThGblBVck5tbGRZN3lLeEdSR1A2SzZCMF9iaERDTDJyRWxmZUdqcmdYUHZjSTVlOWlmbEMtRVk4VmFsTzVyWVkyMkdLVEQ4QVp5a3ZQREJmSkUwVUJucmVrdVlZWW1rOGVyNUVpRUI4eVFGbEF0OUNVZkMxQ1FsLTJiaVRENno5THZNVkF3dWJRMkl4OVZt?oc=5","date":"2026-01-12","type":"regulatory","source":"Center for Biosimilars","summary":"Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships - Center for Biosimilars","headline":"Eye on Pharma: Global Approvals, Launches, and Strategic Partnerships","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQemVXLWYzckNHbFRlVXRseXJadXBJbV95dGNmRDhXNDB6cnluWTROUk1SLWVHTzRlM1Y4RzNuYnkyR3N5R3VFNGNESWQyWUV0UXBnT3hxN0FfMl8xWGp5bUxyT0FWVmkxY1dZT1BrS0o4RDNybXR5bzJneVdMc1RmbTlJQ0xrUDY5MmpYQnpPRHBuSnpOeG9yZU01aHhQZUFN?oc=5","date":"2026-01-09","type":"regulatory","source":"Medical Marketing and Media","summary":"3 regulatory issues for pharma marketers to keep an eye on in 2026 - Medical Marketing and Media","headline":"3 regulatory issues for pharma marketers to keep an eye on in 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPNHNNWjd3M3dZOS1ZVUJjaUhUcGNCTXhpLXFmMEtGT3ZDWWNhM2xyT2tYUnN3SXNNdjV3YnJBcVIyUjIzTFBzYW91LVFNbzV6TjRndkhWbmJSaFpwWWJXaktqakhyWmVRYjI5Rl9XQldCa1d6amdFWmp2ZUdnNFc2YnJ6LWFmMnlqcmhaR0ltR1AxYWNNVE9adVRiakd3UDJsM05KS0Rta0RnaW4wN25XenN3MA?oc=5","date":"2025-10-16","type":"pipeline","source":"Pharma Voice","summary":"J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio - Pharma Voice","headline":"J&J’s orthopedics selloff keeps all eyes on a thriving pharma portfolio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNMWZtdktsWGl2U09vMW8wcVZEYzBYbXpjYVE1RXg3QWZ1aVRJMWtrTElqYmlJemNRRms2UXVIbk5uRGV1Mjl5NkQ3Tjh3RUdCNDVHT3ZnX2lmZ0dTa0RSTGh2Wm5LZjI1QktHYW5MR3pLVklwWTR2SG5KejZJQkd3VjBmRzRwTXh3NGhzeC1GTVVGQW5oN1R1Y3kyMk5TeVlQZUdvXzdHRFNpd0pNM01uTnVtckt1SUREeEpLa1VSbTFJMXprbDVVRVdLeXpvamd0clVkRDZlRkNZS3F0QUR0bzhubw?oc=5","date":"2025-10-01","type":"deal","source":"Reuters","summary":"Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says - Reuters","headline":"Swiss pharma companies eye follow up to Pfizer-US pricing deal, business lobby says","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}